Try our Advanced Search for more refined results
STRECK v. ALLERGAN, INC., ET AL
Case Number:
2:08-cv-05135
Court:
Nature of Suit:
Other Statutes: Commerce ICC Rates, Etc.
Judge:
Firms
- Armstrong Teasdale
- Ballard Spahr
- Berger Montague
- Buchanan Ingersoll
- Campbell Conroy
- Connolly Wells
- Covington & Burling
- Cozen O'Connor
- Dechert LLP
- Dentons
- Faruqi & Faruqi
- Gibson Dunn
- Greenberg Traurig
- Hogan Lovells
- Hyman Phelps
- King & Spalding
- Littler Mendelson
- McCarter & English
- Mintz Levin
- Montgomery McCracken
- Morgan Lewis
- Obermayer Rebmann
- Reed Smith
- Seeger Weiss
- Shook Hardy
- Sidley Austin
- Walden Macht
- Welsh & Recker
Companies
- Abbott Laboratories
- Allergan PLC
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Biogen Inc.
- Boehringer Ingelheim Vetmedica Inc.
- Bristol-Myers Squibb Co.
- Celgene Corp.
- Cencora Inc.
- Cephalon Inc.
- Daiichi Sankyo Co.
- Eisai Co. Ltd.
- Eli Lilly & Co.
- Genzyme Corp.
- Johnson & Johnson
- Merck & Co. Inc.
- Novo Nordisk A S
- Pfizer Inc.
- Purdue Pharma LP
- Santarus, Inc.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Upsher-Smith Laboratories Inc.
Sectors & Industries:
-
July 06, 2015
AstraZeneca, Cephalon Pay $54M To End Medicaid Rebate Row
AstraZeneca LP and Cephalon Inc. have agreed to pay $46.5 million and $7.5 million, respectively, to resolve claims brought by a whistleblower in a False Claims Act suit accusing the drugmakers of knowingly underpaying for rebates owed to the Medicaid Drug Rebate Program, federal prosecutors announced on Monday.
-
November 20, 2012
Judge Won't Revive FCA Medicaid Case Against Allergan, Novo
A Pennsylvania federal judge Friday refused to revive False Claims Act allegations accusing Allergan Inc., Novo Nordisk Inc. and other pharmaceutical companies of defrauding Medicaid by underreporting their average manufacturer prices, saying a request for altered judgment was filed too late.
-
July 05, 2012
4 Drug Cos. Can't Exit FCA Suit Over Medicaid Rebate Prices
A Pennsylvania federal judge on Tuesday gutted a False Claims Act suit that accuses 30 pharmaceutical manufacturers of fraudulently lowering their reported average manufacturer prices in order to pay less in Medicaid rebates to the government, leaving only four defendants.